Butyric acid is the primary energy source for colonocytes, and has shown potential as an alternative to in-feed antibiotics, due to its antimicrobial activity and positive effects on production performance traits of broiler chickens. SILOhealth 104 (SILO S.P.A., Florence, Italy) is a commercial product mainly containing mono-and di-glycerides of butyrate with a small portion of propionic, caprylic, capric, and lauric acid mono-and di-glycerides. Its effects on broiler performance and carcass composition have yet to be evaluated. Four-hundred-eighty day-old male Ross 308 birds were divided into different dietary treatment groups with equal starting weights and fed a diet containing 0, 500, 1,000, 2,000, or 3,000 ppm of SILOhealth 104 for 35 days. There were no significant differences in overall average daily gain or feed: gain ratio with the addition of SILOhealth 104 to the diets (P > 0.05). At 5 wk of age, abdominal fat weight was reduced in birds supplemented with SILOhealth 104 in a dose-responsive manner (P < 0.05), while breast muscle weight increased with supplementation, with significant increases in 2,000 ppm and 3,000 ppm birds compared to controls (P < 0.05). A significant reduction in gene expression of both forkhead box protein O4 and myostatin, 2 factors that can inhibit protein synthesis, was found in the breast muscle of all SILOhealth 104 treated birds (P < 0.05). In addition, gene expression in the adipose tissue, including acetyl-CoA carboxylase alpha and lipoprotein lipase, which are associated with lipid metabolism, was significantly decreased and increased, respectively, by the supplementation of SILOhealth 104 (P < 0.05). These data suggest that the components of SILOhealth 104 can positively affect the deposition of muscle, while reducing abdominal fat deposition in broiler chickens.
INTRODUCTION
From 1970 to 2005, global poultry meat production increased faster than both beef and pork production (Windhorst, 2006) , following the trend for increased consumption (Regmi, 2001) . With this increase expected to continue, combined with the pressures to reduce antibiotic use in feed, finding alternative feed additives could greatly benefit the poultry industry.
Short-chain fatty acids (SCFA) are organic fatty acids produced in the intestinal lumen via bacterial fermentation of undigested dietary carbohydrates (den Besten et al., 2013) , and have been acknowledged as potent inhibiting factors of some pathogenic bacteria in the avian gut (Jozefiak et al., 2004) . Butyric acid (BA) is one of the primary SCFA generated in the distal small intestine and large intestine, and is considered the prime source of energy for colonic enterocytes C Crown copyright 2018. This article contains public sector information licensed under the Open Government Licence v3.0 (http://www. nationalarchives.gov.uk/doc/open-government-licence/version/3/).
Received September 5, 2017. Accepted January 23, 2018. 1 Corresponding author: joshua.gong@agr.gc.ca (Kau et al., 2011) . With the trend towards prudent use of in-feed antibiotics in animal production systems, BA shows potential as an antibiotic substitute. Previous studies have shown that BA has an inhibitory effect on the colonization of Salmonella Typhimurium in the ceca (Cox et al., 1994) and the growth of C. perfringens in vitro (Namkung et al., 2011) . Additionally, BA has been shown to have positive effects on production performance traits of broiler chickens (Leeson et al., 2005) and was reported to significantly reduce total plasma triglycerides and cholesterol by improving insulin sensitivity and increasing fatty acid oxidation, thereby decreasing diet-induced obesity in mice (Gao et al., 2009 ). Free BA is characterized by a strong and unpleasant odor, which makes it impractical for inclusion in diets and has resulted in reduced feed intake (Bolton and Dewar, 1965; Leeson, Namkung, Antongiovanni and Lee, 2005) . Additionally, free BA has been reported to be easily absorbed into the upper gastrointestinal tract (GIT), while its desired target is in the small intestine through to the colon (Rahmatian et al., 2010) . Butyrate glycerides (BG), composed of BA molecules attached to a glycerol molecule, have no such limitations and can release butyrate farther down the GIT via the action of lipase (Sampugna et al., 1967) . The incorporation of mixes of BG into the diets of broiler chickens has shown to improve intestinal development, increase carcass weight at slaughter, and elevate protection against coccidiosis challenge (Leeson, Namkung, Antongiovanni and Lee, 2005; Antongiovanni et al., 2007; Hu and Guo, 2007) . Recently, we reported that including combinations of mono-and tributyrin in the diets of broiler chickens could have a significant effect on muscle growth and fat deposition (Bedford al., 2017) , and that tributyrin supplementation alone could modulate lipid metabolism regardless of broiler strains (Bedford et al., in press) . Transcriptome analysis has shown that BG regulate the expression of genes involved in reduction of synthesis, storage, transportation, and secretion of lipids and fatty acids (Yin et al., 2016) .
SILOhealth 104 (SILO S.P.A., Florence, Italy) is a commercial product mainly containing mono-and diglycerides of butyrate mixed with a portion of the mono-and di-glycerides of other fatty acids. In an effort to investigate the potential of SILOhealth 104 in the diets of broiler chickens, we observed the response of Ross 308 birds in growth performance and related properties to the dietary inclusion of varying levels of SILOhealth 104. The results are reported herein.
MATERIALS AND METHODS

Analysis of SILOhealth 104
The SILOhealth 104 product was first emulsified in water (18.21 mg/mL) with the addition of NaOH (120 mM) to bring the pH to 8.5, then hydrolyzed with HCl/MeOH at 22
• C for one hour. After total hydrolysis, one aliquot of the sample was analyzed directly via gas chromatography (GC) (Model 6890 N; Agilent Technologies, Palo Alto, CA) using a CP-Sil 88 WCOT fused silica column (100 × 0.25 mm i.d. x 0.2 um film thickness; Chrompack, Middleburg, The Netherlands). The column was operated at 45
• C for 4 min, then temperature-programmed at 13
• C/min to 175 • C, held for 27 min, programed at 4
• C/min to 215 • C, and finally held for 35 min; total run time was 86 min, the sample injection volume was 1 μl, and injection mode was splitless. Flame ionization detection (FID) was used. Another aliquot was extracted with hexane and centrifuged. The separated organic layer was passed through a Na 2 SO 4 anhydrous column, then analyzed via GC. The SILOhealth 104 product was then subjected to thin layer chromatography for fractionation with 2 different solvent systems: ethyl acetate: iso-octane: glacial AA (11:5:2) saturated in d-water and hexane: ethyl ether: glacial AA (70:30:1). The separated bands were extracted and solubilized with 3 × 1 ml MeOH. The extracted components were dried under nitrogen stream at 22
• C, weighed, subject to hydrolysis, and further derivatized with NaOCH 3 , then analyzed via GC. The fatty acid methyl esters (FAME) were analyzed by GC. The derivatization step was done by solubilizing the sample in 3 drops of toluene with 1 mL of NaOCH 3 /MeOH, incubating for 30 min at 50
• C, adding 500 μl d-water, and extracting with 1.5 mL of hexane (3 × 0.5 ml). This analysis used 1-monobutyrin (CDS003526, Sigma-Aldrich, St. Louis, MO) as a standard.
Animals and diets
Due to space limitations, this trial was run in 2 separate experiments, each with 240 day-old Ross 308 broiler chicks and a common control group (antibiotic free-basal diet) as a reference. In each experiment, the chicks were allocated based on body weight into one of 3 treatments, with 4 replicates of 20 birds per pen, totaling 80 birds per treatment. In experiment 1, the 3 treatments were control (antibiotic free-basal diet), 500 ppm SILOhealth 104, and 2,000 ppm SILOhealth 104. In experiment 2, the 3 treatments were control, 1,000 ppm SILOhealth 104, and 3,000 ppm SILOhealth 104. Birds were fed a starter diet from d 1 to 15, a grower diet from d 15 to 28, and a finisher diet from d 29 to 35. The basal diets are outlined in Table 1 . Birds were reared in pens and allowed ad libitum access to feed and water. Birds were maintained at a brooding temperature of 32
• C for 7 d after which the environmental temperature was gradually reduced to 22
• C from d 7 to d 35. Photoperiod was 23 h for d 1 to 3, 18 h for d 4 to 17, and 20 h for d 18 to 35. This follows standard brooding practice and standard operating procedures at the Arkell Poultry Research Station, University of Guelph. Chickens were group-weighed weekly, and feed intake was recorded at the same time. The experimental use of animals and procedures were ap-proved by the University of Guelph's Animal Care Committee (AUP# 3176) in accordance with the Canadian Council on Animal Care's guidelines.
Sample collection
On d 21 and 35 for each treatment, 2 birds per pen (8 birds per treatment) were randomly selected for sample collection. After weighing, blood samples were collected from the brachial vein of each bird, kept on ice, and then centrifuged at 5,000 g for 15 min at 4
• C. The serum was immediately transferred into a separate tube, and stored at −80
• C until analysis. Following blood collection, birds were euthanized via cervical dislocation. The abdominal fat pad (from the proventriculus surrounding the gizzard down to the cloaca) was removed and weighed. The small and large intestines were removed, and the length of each recorded. Following sampling and emptying, the small intestine weight was recorded. At the 35 d sampling, the entire breast muscle (pectoralis major and supracoracoidus) was removed and weighed. All collected tissue samples were both treated immediately with RNAlater R Stabilization Solution (Ambion Inc., Austin, TX) for future RNA work, and frozen directly in liquid nitrogen for downstream protein and lipid analyses. Half-centimeter pieces were excised into RNAlater R , and larger pieces were flash frozen. The tissues sampled in this manner were the liver, breast muscle, and abdominal fat.
Lipid extraction
Methods for lipid extraction and composition analysis were adapted from Kraft et al. (2008) . Muscle tissue was minced in a Waring commercial blender (Conair, Hightstown, NJ), then freeze-dried and stored at -80
• C. Briefly, lipids were extracted from pulverized muscle samples (3 g) using dichloromethane: methanol (1:1, v/v). Solvent was then roto-evaporated to obtain the weight of total lipids in the sample.
RNA extraction, reverse transcription, and quantitative PCR
The methods of RNA extraction, reverse transcription, and quantitative PCR assays were described previously (Sarson et al., 2009) . To extract RNA from the breast muscle and abdominal fat, sections of approximately 1 mm were cut from a 0.5 cm sample segment that had been stored in RNAlater R Stabilization Solution (AM7020, Thermo Fisher Scientific, Waltham, MA) at −80
• C. Total RNA was prepared using Trizol (15, Thermo Fisher Scientific, Waltham, MA) according to manufacturer's instruction. Briefly, tissues were homogenized in Trizol reagent using a Brinkmann Polytron homogenizer (PT4000, Kinematica, Lucern, Switzerland), then centrifuged to obtain the cleared supernatant. This supernatant was then extracted with chloroform, then isopropanol was added for RNA precipitation. The resulting RNA precipitate was pelleted by centrifugation, then washed with ethanol and resuspended in RNase-free water. Total RNA was treated with DNase I (AMPD1, Sigma-Aldrich, St. Louis, MO). First-strand complementary DNA was synthesized using the SuperScript R III First-Strand Synthesis System (18,080-051, Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instruction. Quantitative PCR was performed using a S1000 Thermocycler (1,852,148, Bio-Rad Laboratories, Hercules, CA) with iTaq TM Universal SYBR R Green Supermix (1,725,121, Bio-Rad Laboratories, Hercules, CA). Each reaction was performed in triplicate under the following conditions: denaturation at 95
• C for 15 s, annealing at 60
• C for 30 s, extension at 72
• C for 30 s, and a subsequent melting curve (55 to 95
• C) with continuous fluorescent measurement and final cooling to 22
• C. Primer sequences are outlined in Table 2 . Relative mRNA levels were determined using the comparative Ct method, using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the internal reference gene (Schmittgen and Livak, 2008) .
Statistical analysis
The data were statistically analyzed by one-way ANOVA using the MIXED procedure (SAS Release 9.3, SAS Institute Inc., Cary, NC). The2 common non-supplemental controls in the separate experiments showed no significant difference in growth performance. The data from the 2 experiments were then combined for the statistical analysis accordingly. Significant differences (P ≤ 0.05) between treatment means were identified by the Tukey-Kramer test. The dose responses of abdominal fat or breast muscle weight relative to the body weight to the applied concentrations of SILOhealth 104 were examined by the REG procedure of SAS.
RESULTS
Composition of SILOhealth 104
Based on analysis, the approximate composition of SILOhealth 104 is 40 to 50% monobutyrin, 40 to 50% mono-and di-glycerides of other fatty acids, with the remainder being dibutyrin. Of the other fatty acids, caprylic and capric are the most prominent (30 to 40%), with propionic, lauric, pelargonic, undecylic, myristic, palmitic, stearic, and oleic acids also present (10 to 20%).
Growth performance of birds supplemented with SILOhealth 104
There were no significant differences in average daily gain (ADG) through the wk of the trial, nor was there a significant difference in the overall ADG (P > 0.05; Table 3 ). In wk 1, 1,000 ppm birds had a significantly higher feed: gain ratio compared to control, 500 ppm, and 2,000 ppm birds, while 2,000 ppm birds had a significantly lower feed: gain ratio compared to 3,000 ppm birds (P < 0.05; Table 3 ). There were no significant treatment differences in feed: gain ratio in wk 2, 3, or 4 (P > 0.05; Table 3 ). In wk 5, 500 ppm and 2,000 ppm birds had a significantly higher feed: gain ratio compared to 1,000 and 3,000 ppm birds (P < 0.05; Table 3 ). These weekly differences did not lead to significant differences in overall feed: gain ratios (P > 0.05; Table 3 ). There were no significant differences in the absolute body weights of the birds throughout the trial (P > 0.05; Table 3 ). The feed intake among groups did not differ (P > 0.05; data not shown). At 3 wk of age, 1,000 ppm birds had a significantly higher small intestine weight relative to body weight compared to 500 ppm birds (P < 0.05; Figure 1A ). At 5 wk of age, there were no differences in small intestine weight relative to body weight (P > 0.05; Figure 1B) . SILOhealth 104 supplementation did not affect small intestine length or large intestine length relative to body weight at 3 or 5 wk of age (P > 0.05; Figure 1C , D).
SILOhealth 104 effects on breast muscle and abdominal fat pad deposition
There was no significant difference in absolute abdominal fat weight with the addition of SILOhealth 104 at 3 wk of age (P > 0.05; Figure 2A ), but regression analysis showed that there was a significant dose response with increasing SILOhealth 104 for a decrease in abdominal fat weight relative to body weight at 3 wk of age (y = 1.1492-0.0000567x; P = 0.0209; Figure 2B ). At 5 wk of age, the addition of SILOhealth 104 at 3,000 ppm caused a significant reduction in absolute abdominal fat weight compared to control birds (P < 0.05; Figure 2C ). Regression analysis showed that there was a significant dose response with increasing SILOhealth 104 for a decrease in abdominal fat weight relative to body weight at 5 wk of age (y = 1.4645-0.0000985x; P < 0.0001; Figure 2D ).
There was no significant difference in absolute breast muscle weight at 5 wk of age (P > 0.05; Figure 3A ), but regression analysis showed that there was a significant dose response with increasing SILOhealth 104 inclusion levels for an increase in breast muscle weight relative to body weight (y = 18.428 + 0.000450x; P = 0.0074; Figure 3B ). In particular, breast muscle weight relative to body weight at 5 wk of age was significantly increased in 2,000 ppm and 3,000 ppm birds compared to controls (P < 0.05; Table 4 ). There was a numerical trend for the supplementation of SILOhealth 104 to increase the deposition of fat in the breast muscle, but it was not significant (P > 0.05; Table 4 ).
Differential expression of genes associated with muscle or fat deposition with SILOhealth 104 supplementation
Among the 3 factors associated with muscle deposition, gene expression of both forkhead box protein O4 (FOXO4) and myostatin in the breast muscle at 5 wk of age was significantly decreased in birds receiving all inclusion levels of SILOhealth 104 compared to controls (P < 0.05; Figure 4A , B). There were no significant differences in mechanistic target of rapamycin (mTOR) expression in the breast muscle across treatment groups (P > 0.05; Figure 4C ).
There were no significant differences in fatty acid synthase (FASN) or peroxisome proliferator-activated receptor gamma (PPARG) expression, which are associated with lipid deposition, in the abdominal fat at 5 wk of age with the addition of SILOhealth 104 (P > 0.05; data not shown). Gene expression of acetylCoA carboxylase alpha (ACACA) at 5 wk of age in the abdominal fat was significantly lower in 1,000 and 3,000 ppm birds compared to controls (P < 0.05; Figure 5A ). At 5 wk of age, expression of lipoprotein lipase (LPL) in the abdominal fat was significantly higher in 2,000 and 3,000 ppm birds compared with controls (P < 0.05; Figure 5B ). . Regression analysis of abdominal fat weight relative to body weight at 5 wk of age (y = 1.4645-0.0000985x; P < 0.0001). Different letters indicate significant differences among treatments (P < 0.05).
DISCUSSION
In order to interpret the results from the feeding trial, we first performed analysis on the SILOhealth 104 to determine its composition. Using the combined strategies of GC together with thin layer chromatography, it was determined that the best approximation for the formulation of SILOhealth 104 is 40 to 50% monobutyrin, 40 to 50% mono-and di-glycerides of other fatty acids (including caprylic and capric as the most prominent, with propionic, lauric, pelargonic, undecylic, myristic, palmitic, stearic, and oleic acids) with the remainder being dibutyrin. This means that the results presented in this study could be attributed to not only BG, but also the glycerides of other fatty acids.
While there was no overall difference observed in ADG, in wk 4 the addition of SILOhealth 104 improved the growth of birds at all inclusion levels. There was also no effect on overall feeding efficiency (feed: gain) with supplementation; however, we observed varied feeding efficiency in individual wk among treatment groups compared to control birds. Of the most interest in the present study was the effect of SILOhealth 104 on abdominal fat and breast muscle deposition. Both of these attributes changed in a dose-response manner to the increasing inclusion of SILOhealth 104, with relative abdominal fat deposition decreasing, and relative breast muscle deposition increasing. Considering gene expression in the breast muscle, SILOhealth 104 decreased the gene expression of FOXO4 and myostatin, without changing levels of mTOR. The mTOR pathway in muscle is one of the regulators of muscle hypertrophy and atrophy, but does not appear to be affected by SILOhealth 104 supplementation (Bodine et al., 2001) . Myostatin has been well established as a negative regulator of skeletal muscle mass; mice lacking the myostatin gene show a dramatic increase in muscle mass accompanied by a decrease in adipogenesis (Lee and McPherron, 2001; Lin et al., 2002 ). It appears that the decreased myostatin expression observed in the birds of the present study had a major effect on both the muscle and fat deposition. It has been shown that FOXO4 is responsible for the increase in atrogin-1, a protein that is expressed during muscle atrophy (Gomes et al., 2001; Moylan et al., 2008) . This suggests that the decreased FOXO4 expression in the birds of the present study may be leading to improved breast muscle deposition through reduced atrophy levels. Additionally, FOXO4 has been shown to enhance apoptosis (Wang et al., 2014) . The inhibition of this pathway could be another contributing factor to the improved muscle deposition with SILOhealth 104 supplementation.
Decreased abdominal fat deposition, in connection with BA has been previously reported (Panda et al., 2009) . In a recent study conducted by our group using RNAseq techniques, BG have been shown to affect some of the major pathways of lipid metabolism in both the jejunum and liver (Yin et al., 2016) . In addition to BA, propionic acid supplemented into diets of broiler chickens also was reported to reduce abdominal fat deposition, an effect that also may have contributed to the abdominal fat reduction observed in the current study. Considering the presented expression of lipid metabolism associated genes in the abdominal fat tissues, there were no changes in the expression of FASN (a multi-enzyme protein that catalyzes fatty acid synthesis) or PPARG (a stimulator of lipid uptake and adipogenesis) with the addition of SILOhealth 104. However, ACACA expression was decreased in 1,000 and 3,000 ppm birds, and LPL expression was increased in 2,000 and 3,000 ppm birds compared to controls. Acetyl-CoA carboxylase is one of the regulators of the metabolism of fatty acids, stimulating the anabolism of fatty acids when active. While the primary site for fatty acid synthesis in poultry is the liver, the depressed level of ACACA observed in the abdominal fat could explain the lowered fat deposition observed. Decreased ACACA activity has been previously linked with decreased abdominal fat deposition in broiler chicks (Santoso et al., 1995) . LPL has been shown to be a mediator in the uptake of plasma triglycerides into extra-hepatic tissues; however, when comparing lean and fat chicken lines, they did not differ in LPL activity in adipocytes (Hermier et al., 1989) . The increased LPL expression observed in this study seems contradictory to the decrease in abdominal fat deposition detected in birds fed the higher levels of SILOhealth 104. The reason underlying this observation is unclear, and requires further investigation.
In conclusion, while SILOhealth 104 did not show an effect on overall growth performance of broilers in this study, there were significant effects on the deposition of both the breast muscle and adipose tissue. While SILOhealth 104 has multiple components and the observed effects may not be attributed only to BG, the product holds a promise for application in broiler production, especially with the increasing global demand for poultry products. 
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